FAP and neoplasm: Breakdown into subsets of immune cells on day 8 pi for the 177Lu-FAP-2287 monotherapy and 177Lu-FAP-2287 plus anti-PD-1 combination showed monocytic myeloid-derived suppressor cells (Mo-MDSCs) significantly increased from 22.3% of CD45+ cells for vehicle control to 34.9% and 30.6%, respectively (P < 0.05, Fig. 3B-C), while no changes in tumor associated macrophages (TAMs) were observed.